{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T10:27:05Z","timestamp":1760783225991},"reference-count":25,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2010,11,1]],"date-time":"2010-11-01T00:00:00Z","timestamp":1288569600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brain and Development"],"published-print":{"date-parts":[[2010,11]]},"DOI":"10.1016\/j.braindev.2009.12.005","type":"journal-article","created":{"date-parts":[[2010,1,15]],"date-time":"2010-01-15T06:06:11Z","timestamp":1263535571000},"page":"805-809","source":"Crossref","is-referenced-by-count":9,"title":["The effect of N-octyl-\u03b2-valienamine on \u03b2-glucosidase activity in tissues of normal mice"],"prefix":"10.1016","volume":"32","author":[{"given":"Zhuo","family":"Luan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haruaki","family":"Ninomiya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kousaku","family":"Ohno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seiichiro","family":"Ogawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takatoshi","family":"Kubo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masami","family":"Iida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiyuki","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.braindev.2009.12.005_bib1","series-title":"The metabolic and molecular bases of inherited disease","first-page":"3635","article-title":"Gaucher disease","author":"Beutler","year":"2001"},{"key":"10.1016\/j.braindev.2009.12.005_bib2","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.cbpa.2007.05.035","article-title":"Gaucher disease","volume":"11","author":"Butters","year":"2007","journal-title":"Curr Opin Chem Biol"},{"key":"10.1016\/j.braindev.2009.12.005_bib3","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1056\/NEJM199105233242104","article-title":"Replacement therapy for inherited enzyme deficiency-macrophage-targeted glucocerebrosidase for Gaucher\u2019s disease","volume":"324","author":"Barton","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1016\/j.braindev.2009.12.005_bib4","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1016\/S0140-6736(00)02161-9","article-title":"Novel oral treatment of Gaucher\u2019s disease with N-butyldeoxynojirimycin (OGT918) to decrease substrate biosynthesis","volume":"355","author":"Cox","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.braindev.2009.12.005_bib5","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S0268-960X(98)90023-6","article-title":"Enzyme therapy for Gaucher disease: the first 5 years","volume":"12","author":"Grabowski","year":"1998","journal-title":"Blood Rev"},{"key":"10.1016\/j.braindev.2009.12.005_bib6","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1023\/A:1010335505357","article-title":"Inhibition of substrate synthesis as a strategy for glycolipids lysosomal storage disease therapy","volume":"24","author":"Platt","year":"2001","journal-title":"J Inherit Metab Dis"},{"key":"10.1016\/j.braindev.2009.12.005_bib7","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1002\/ana.410420412","article-title":"Prospective study of neurological responses to treatment with macrophage-targeted glucocerebrosidase in patients with type 3 Gaucher\u2019s disease","volume":"42","author":"Schiffmann","year":"1997","journal-title":"Ann Neurol"},{"key":"10.1016\/j.braindev.2009.12.005_bib8","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1002\/(SICI)1096-8628(19970711)71:1<16::AID-AJMG3>3.0.CO;2-O","article-title":"Gaucher disease: enzyme therapy in the acute neuronopathic variant","volume":"71","author":"Prows","year":"1997","journal-title":"Am J Med Genet"},{"key":"10.1016\/j.braindev.2009.12.005_bib9","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s004310000630","article-title":"Improvement of neurological symptoms by enzyme replacement therapy for Gaucher disease type IIIb","volume":"160","author":"Aoki","year":"2001","journal-title":"Eur J Pediatr"},{"key":"10.1016\/j.braindev.2009.12.005_bib10","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s10545-006-0272-5","article-title":"Substrate reduction therapy of glycosphingolipid storage disorders","volume":"29","author":"Aerts","year":"2006","journal-title":"J Inherit Metab Dis"},{"key":"10.1016\/j.braindev.2009.12.005_bib11","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1093\/hmg\/ddi240","article-title":"ER retention and degradation as the molecular basis underlying Gaucher disease heterogeneity","volume":"14","author":"Ron","year":"2005","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.braindev.2009.12.005_bib12","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/0960-894X(96)00146-1","article-title":"Synthesis of potent beta-d-glucocerebrosidase inhibitors: N-alkyl-\u03b2-valienamines","volume":"6","author":"Ogawa","year":"1996","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.braindev.2009.12.005_bib13","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.bbadis.2004.03.007","article-title":"N-Octyl-\u03b2-valienamine upregulates activity of F213I mutant \u03b2-glucosidase in cultured cells: a potential chemical chaperone therapy for Gaucher disease","volume":"1689","author":"Lin","year":"2004","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.braindev.2009.12.005_bib14","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.bbadis.2007.02.003","article-title":"Enzyme enhancement activity of N-octyl-beta-valienamine on beta-glucosidase mutants associated with Gaucher disease","volume":"1772","author":"Lei","year":"2007","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.braindev.2009.12.005_bib15","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1038\/sj.embor.embor873","article-title":"X-ray structure of human acid-beta-glucosidase, the defective enzyme in Gaucher disease","volume":"4","author":"Dvir","year":"2003","journal-title":"EMBO Rep"},{"key":"10.1016\/j.braindev.2009.12.005_bib16","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1002\/ana.21284","article-title":"Chemical chaperone therapy: clinical effect in murine G(M1)-gangliosidosis","volume":"62","author":"Suzuki","year":"2007","journal-title":"Ann Neurol"},{"key":"10.1016\/j.braindev.2009.12.005_bib17","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/0009-9120(87)90010-5","article-title":"Effect of a heat-stable factor in human placenta on glucosylceramidase, glucosylsphingosine glucosyl hydrolase, and acid \u03b2-glucosidase activities","volume":"20","author":"Vaccaro","year":"1987","journal-title":"Clin Biochem"},{"key":"10.1016\/j.braindev.2009.12.005_bib18","doi-asserted-by":"crossref","first-page":"15912","DOI":"10.1073\/pnas.2536657100","article-title":"Chemical chaperone therapy for brain pathology in G(M1)-gangliosidosis","volume":"100","author":"Matsuda","year":"2003","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.braindev.2009.12.005_bib19","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.braindev.2006.02.002","article-title":"Fibroblast screening for chaperone therapy in \u03b2-galactosidosis","volume":"28","author":"Iwasaki","year":"2006","journal-title":"Brain Dev"},{"key":"10.1016\/j.braindev.2009.12.005_bib20","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1002\/cbic.200900442","article-title":"Chaperone activity of bicyclic nojirimycin analogues for Gaucher mutations in comparison with N-(n-nonyl) deoxynojirimycin","volume":"10","author":"Luan","year":"2009","journal-title":"Chembiochem"},{"key":"10.1016\/j.braindev.2009.12.005_bib21","doi-asserted-by":"crossref","unstructured":"Z. Luan, L. Li, H. Ninomiya, K. Ohno, S. Ogawa, T. Kubo et al., The pharmacological chaperone effect of N-octyl-beta-valienamine on human mutant acid beta-glucosidases, Blood Cells Mol Dis, 2009, doi:10.1016\/j.bcmd.2009.10.003.","DOI":"10.1016\/j.bcmd.2009.10.003"},{"key":"10.1016\/j.braindev.2009.12.005_bib22","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/4801","article-title":"Accelerated transport and maturation of lysosomeal \u03b1-galactosidase A in Fabry lymphoblasts by an enzyme inhibitor","volume":"5","author":"Fan","year":"1999","journal-title":"Nat Med"},{"key":"10.1016\/j.braindev.2009.12.005_bib23","doi-asserted-by":"crossref","first-page":"15428","DOI":"10.1073\/pnas.192582899","article-title":"Chemical chaperones increase the cellular activity of N370S \u03b2-glucosidase: a therapeutic strategy for Gaucher disease","volume":"99","author":"Sawkar","year":"2002","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.braindev.2009.12.005_bib24","doi-asserted-by":"crossref","first-page":"13478","DOI":"10.1074\/jbc.M308523200","article-title":"Pharmacological enhancement of \u03b2-hexosaminidase activity in fibroblasts from adult Tay-Sachs and Sandhoff patients","volume":"279","author":"Tropak","year":"2004","journal-title":"J Biol Chem"},{"key":"10.1016\/j.braindev.2009.12.005_bib25","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1038\/sj.mt.6300074","article-title":"Pharmacological enhancement of mutated \u03b1-glucosidase activity in fibroblasts from patients with Pompe disease","volume":"15","author":"Parenti","year":"2007","journal-title":"Mol Ther"}],"container-title":["Brain and Development"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0387760409003404?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0387760409003404?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,25]],"date-time":"2019-05-25T05:03:44Z","timestamp":1558760624000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0387760409003404"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,11]]},"references-count":25,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2010,11]]}},"alternative-id":["S0387760409003404"],"URL":"https:\/\/doi.org\/10.1016\/j.braindev.2009.12.005","relation":{},"ISSN":["0387-7604"],"issn-type":[{"value":"0387-7604","type":"print"}],"subject":[],"published":{"date-parts":[[2010,11]]}}}